The Australia in vitro fertilization market was valued at USD 30.57 Million in 2025 and is expected to grow at a CAGR of 9.50%, reaching USD 75.76 Million by 2035. The market growth is driven by growing acceptance of delayed parenthood, supportive government initiatives, and rising prevalence of infertility cases. Increasing access to advanced reproductive technologies, coupled with innovations in genetic testing and embryo freezing, is anticipated to enhance adoption. Expanding fertility clinics and improving healthcare infrastructure are further expected to accelerate growth during the forecast period.
Base Year
Historical Period
Forecast Period
In March 2025, the Australian Government expanded PBS listings to improve affordability of IVF treatments like Pergoveris®, expected to ease financial barriers for thousands of women, thereby fueling growth in the country’s IVF market.
One of the major market trends includes government support for fertility research. For instance, in September 2024, UNSW received a USD 1.7 million grant to establish FM-DATA, fostering innovation and driving growth in the market.
The market is experiencing steady growth, driven by rising infertility cases, technological advancements, supportive regulations, and the active role of key players in enhancing accessibility, innovation, and treatment success rates.
Compound Annual Growth Rate
9.5%
Value in USD Million
2026-2035
*this image is indicative*
In vitro fertilization has emerged as a widely adopted assisted reproductive technology, offering hope to individuals and couples facing fertility challenges by enabling successful conception through advanced clinical procedures. In Australia, the in vitro fertilization market is expanding due to rising infertility rates, delayed parenthood trends, and increasing technological advancements in reproductive healthcare. Supportive government initiatives, improved clinical outcomes, and growing awareness are further fueling adoption across the country. The market is poised to grow at a CAGR of 9.50% during the forecast period of 2026-2035, reflecting strong demand and evolving patient preferences.
Technological Advancements to Drive the Growth in the IVF Market in Australia
The introduction of advanced sperm selection technologies aimed at improving IVF success rates is a key factor driving the growth in the market. In April 2023, researchers from the University of Technology Sydney (UTS) and NeoGenix Biosciences developed a 3D-printed microfluidic device designed to replicate the natural sperm selection process, resulting in an 85% improvement in DNA integrity and a 90% reduction in sperm cell death compared to conventional methods. Such innovations enhance treatment outcomes, reduce unsuccessful cycles, and are expected to significantly strengthen market growth in the coming years.
The market is witnessing several trends, such as patient-centric decision support and innovations in sperm purification technology.
Patient-Centric Decision Support is Likely to Enhance Market Demand
The market is witnessing an increasing emphasis on evidence-based decision support tools that empower patients to make informed treatment choices. In April 2025, the launch of a University of Melbourne, led website dedicated to providing impartial, research-driven insights into IVF “add-ons” highlighted this shift. By addressing misinformation and helping patients evaluate optional procedures with clarity, such initiatives are improving transparency, patient confidence, and treatment outcomes. This growing focus on patient education is expected to significantly enhance market growth.
Advancement in Sperm Purification Technology Likely to Boost Market Growth
The growing focus on advanced sperm purification methods to improve fertilization outcomes is a key trend shaping the market. In December 2024, research at the University of Adelaide received significant funding to develop a novel device that mimics natural biological processes to filter high-quality sperm with superior DNA integrity. This innovation aims to increase pregnancy success rates, reduce treatment failures, and improve long-term health outcomes for IVF children. Such technological advancements are expected to enhance patient confidence and significantly contribute to market growth.
Conventional IVF to Lead the Market Segmentation Based on Procedure
Several types of procedures are included in the market such as conventional IVF, IVF with intracytoplasmic sperm injections, mineral IVF, IVF with donor eggs and other procedures. Among these, conventional IVF is expected to lead the market, driven by its wide clinical acceptance, cost-effectiveness, and applicability across diverse infertility conditions. According to the Australian and New Zealand assisted reproduction database, approximately 20,000 babies are born from IVF treatment in Australia every year, highlighting the sustained preference for conventional IVF. While IVF and donor egg treatments are gaining momentum, conventional IVF remains the most practiced approach.
The key features of the market report comprise patent analysis, funding and investment analysis, and strategic initiatives by the leading players. The major companies in the market are as follows:
Vitrolife is a global company providing medical devices, consumables, culture media, and genetic testing services for assisted reproduction. In Australia, Vitrolife supplies culture media and ICSI/IVF media that are registered with the Therapeutic Goods Administration (TGA), including assisted reproduction procedure dishes, IVF and ICSI culture media. The company also invests in innovation relevant to the IVF workflow (for example, with media optimized for time-lapse or reduced stress on embryos), and supports clinics through education, quality control, and ongoing R&D to improve outcomes.
Cooper Surgical (via its CooperSurgical / CooperCompanies group) offers products, services and technologies spanning the ART process. Globally, it covers devices, fertility media, diagnostics (including genetic testing), cryogenics, and software related to IVF labs. In Australia, the company is active via partnerships and supplying product lines for women’s health and fertility clinics. For example, CooperSurgical has entered a multi-year collaboration with Virtus Health (a major Australian IVF/ART provider) to bring together its technology (e.g. preimplantation genetic testing, cryogenics, digital and lab systems) with Virtus’s clinical operations. The company also supplies fertility-related devices and consumables through distributors (e.g., media, catheters, instruments) to IVF labs, supporting procedural components across clinics.
GE Healthcare provides medical technologies, diagnostics, and equipment more broadly, including imaging, monitoring, ultrasound etc. Its role in IVF/ART in Australia is less focused on consumables and media, more on supporting infrastructure, diagnostic imaging, laboratory and monitoring equipment, possibly lab automation or monitoring tools. It has also partnered with reproductive-health technology providers (e.g. Vitrolife) to improve offerings in ART/IVF, combining strengths in diagnostics, monitoring, and imaging components that support fertility clinics. Thus its engagement is upstream of the embryo culture media etc., more in equipment, imaging & lab diagnostics that help fertility clinics operate at high standard.
Thermo Fisher is a large supplier of lab consumables, diagnostics, reagents, equipment, and services. In the IVF/ART context in Australia, it provides items such as IVF/assisted reproduction procedure dishes, tubes, culture/disposables, as well as genetic testing tools and in vitro diagnostics (IVDs) used for hormone tests, embryo / embryo culture, genetic screening, etc. It also ensures its products are registered under the Australian regulatory system (TGA) when required. Thermo Fisher supports fertility labs’ requirements for reliability, quality, regulatory compliance, and supports pre-implantation genetic testing by providing sequencing or diagnostic platforms (e.g. NGS, reagents) that enable screening embryos.
*Please note that this is only a partial list; the complete list of key players is available in the full report. Additionally, the list of key players can be customized to better suit your needs.*
Other key players in the market include Eppendorf, Esco Micro Pte. Ltd., Fertipro NV, Olympus, Corning Incorporated and Carl Zeiss Microscopy GmbH.
The market report offers a detailed analysis of the market based on the following segments:
Market Breakup by Type
Market Breakup by Type of Cycle
Market Breakup by Procedure
Market Breakup by End User
Upto 15% Off
USD
$3099 $2789
$1999 $1799
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
| REPORT FEATURES | DETAILS |
| Base Year | 2025 |
| Historical Period | 2019-2025 |
| Forecast Period | 2026-2035 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Product |
|
| Breakup by Type of Cycle |
|
| Breakup by Procedure |
|
| Breakup by End User |
|
| Market Dynamics |
|
| Supplier Landscape |
|
| Companies Covered |
|
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Datasheet
One User
USD 1,999
USD 1,799
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share